Forecasts data is unavailable for this security.

Consensus recommendation

As of Sep 13, 2019, the consensus forecast amongst 2 polled investment analysts covering Novartis AG (ADR) advises investors to purchase equity in the company. This has been the consensus forecast since the sentiment of investment analysts improved on Sep 22, 2018. The previous consensus forecast advised that Novartis AG (ADR) would outperform the market.
  • 1yr ago
  • 3M ago
  • 2M ago
  • 1M ago
  • Latest
Select bar for recommendation details.

Share price forecast

The 2 analysts offering 12 month price targets for Novartis AG (ADR) have a median target of 101.00, with a high estimate of 102.00 and a low estimate of 100.00. The median estimate represents a 16.72% increase from the last price of 86.53.


In 2018, Novartis AG reported a dividend of 2.94 USD, which represents a 8.05% increase over last year. The 17 analysts covering the company expect dividends of 2.97 USD for the upcoming fiscal year, an increase of 1.01%.
Div growth (TTM)8.05%
More ▼

Earnings history & estimates

On Jul 18, 2019, Novartis AG (ADR) reported 2nd quarter 2019 earnings of 1.34 per share. This result exceeded the 1.22 consensus of the 7 analysts covering the company and exceeded last year's 2nd quarter results by 3.88%.
The next earnings announcement is expected on Oct 22, 2019.
Average growth rate+1.14%
Novartis AG (ADR) reported annual 2018 earnings of 5.15 per share on Jan 30, 2019.
The next earnings announcement from Novartis AG (ADR) is expected the week of Jan 28, 2020.
Average growth rate-0.25%
More ▼

Revenue history & estimates

Novartis AG (ADR) had 2nd quarter 2019 revenues of 11.76bn. This bettered the 11.50bn consensus of the 7 analysts covering the company. This was 10.59% below the prior year's 2nd quarter results.
Average growth rate-2.36%
Novartis AG (ADR) had revenues for the full year 2018 of 51.90bn. This was 5.68% above the prior year's results.
Average growth rate-2.43%
More ▼
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.